So we know what we will be studying: The study
Post# of 148095
The study will evaluate the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer (“CRC”).
Investors Hangout: https://investorshangout.com/post/view?id=672...z8qcVP9Guq
What else do we know besides beginning enrollment timeframe?